Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathryn C Arbour

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
JAMA|August 28, 2019
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A ReviewKathryn C Arbour, Gregory J Riely
Hematology/Oncology Clinics of North America|December 4, 2016
Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung CancerKathryn C Arbour, Gregory J Riely
Cancer Research|January 9, 2026
MTAP Deletion in Oncogenesis: A Synthetic Lethality ScenarioJordi Rodon, Melissa L Johnson, Ben George, et al.
Current Oncology Reports|March 18, 2017
Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to TherapyJoshua K Sabari, Fernando Santini, Isabella Bergagnini, et al.
Oncotargets and Therapy|April 25, 2017
The activity, safety, and evolving role of brigatinib in patients with <i>ALK</i>-rearranged non-small cell lung cancersJoshua K Sabari, Fernando C Santini, Alison M Schram, et al.
Plos One|August 4, 2017
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumorsKathryn C Arbour, Jarushka Naidoo, Keith E Steele, et al.
Cancer|September 24, 2017
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastasesKathryn C Arbour, Mark G Kris, Gregory J Riely, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2021
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung CancerKathryn C Arbour, Hira Rizvi, Andrew J Plodkowski, et al.
JCO Precision Oncology|June 29, 2023
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced <i>KRAS G12C</i>-Mutant Non-Small Cell Lung CancerRohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, et al.
Journal of the National Cancer Institute|August 22, 2025
The impact of eligibility criteria on KRASG12C inhibitor trials in patients with NSCLCMargaux Wooster, Michael May, Prashasti Agrawal, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
JAMA|August 28, 2019
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A ReviewKathryn C Arbour, Gregory J Riely
Hematology/Oncology Clinics of North America|December 4, 2016
Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung CancerKathryn C Arbour, Gregory J Riely
Cancer Research|January 9, 2026
MTAP Deletion in Oncogenesis: A Synthetic Lethality ScenarioJordi Rodon, Melissa L Johnson, Ben George, et al.
Current Oncology Reports|March 18, 2017
Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to TherapyJoshua K Sabari, Fernando Santini, Isabella Bergagnini, et al.
Oncotargets and Therapy|April 25, 2017
The activity, safety, and evolving role of brigatinib in patients with <i>ALK</i>-rearranged non-small cell lung cancersJoshua K Sabari, Fernando C Santini, Alison M Schram, et al.
Plos One|August 4, 2017
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumorsKathryn C Arbour, Jarushka Naidoo, Keith E Steele, et al.
Cancer|September 24, 2017
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastasesKathryn C Arbour, Mark G Kris, Gregory J Riely, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2021
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung CancerKathryn C Arbour, Hira Rizvi, Andrew J Plodkowski, et al.
JCO Precision Oncology|June 29, 2023
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced <i>KRAS G12C</i>-Mutant Non-Small Cell Lung CancerRohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, et al.
Journal of the National Cancer Institute|August 22, 2025
The impact of eligibility criteria on KRASG12C inhibitor trials in patients with NSCLCMargaux Wooster, Michael May, Prashasti Agrawal, et al.
Pageof 4